Skip to content

Study · Non-randomized trial · 2005

6 results

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles.

Simon C, Oberyé J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B, Pellicer A

Human reproduction (Oxford, England)5 Aug 2005Cited by 99 (Europe PMC)

PMID16085660 (opens in a new tab)DOI10.1093/humrep/dei243 (opens in a new tab)PepBankPUB-16085660
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialMechanism

    In oocyte donors, endometrial dating, steroid receptors and pinopodes were comparable between high- and standard-dose ganirelix at HCG +7.

    In plain wordsIn oocyte donors, endometrial dating, steroid receptors and pinopodes were comparable between high- and standard-dose ganirelix at HCG +7.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedEndometrial dating, steroid receptors and pinopodes
    Study

    n: not reported in source

    Comparator
    standard-dose ganirelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 mg/dayAs given in this study (human).

    Source sentences

    Summary
    At HCG +7, endometrial dating, steroid receptors and the presence of pinopodes were comparable in both GnRH antagonist groups and in the natural cycle.
    4 context sentences
    Summary · context
    This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles.
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.
    Summary · context
    Gene expression profiles were also studied.
  2. 02HumanNon-randomized trialMechanism

    In oocyte donors, window-of-implantation gene expression after standard- or high-dose ganirelix was closer to natural-cycle patterns than after buserelin.

    In plain wordsIn oocyte donors, implantation gene expression after standard- or high-dose ganirelix was closer to natural-cycle patterns than after buserelin.

    Peptide
    Ganirelix
    Outcome
    Not applicableWindow of implantation gene expression
    Study

    n: not reported in source

    Comparator
    buserelin 0.6 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (standard) and 2 mg/day (high)As given in this study (human).

    Source sentences

    Summary
    For window of implantation genes, expression patterns were closer to those in the natural cycle following standard- or high-dose ganirelix than after buserelin administration.
    4 context sentences
    Summary · context
    This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles.
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.
    Summary · context
    Gene expression profiles were also studied.
  3. 03HumanNon-randomized trialMechanism

    In oocyte donors, window-of-implantation gene expression patterns after standard- or high-dose ganirelix were closer to natural-cycle patterns than after buserelin.

    In plain wordsIn oocyte donors, implantation-window gene expression after standard- or high-dose ganirelix was closer to the natural cycle than after buserelin.

    Peptide
    Ganirelix
    Outcome
    Not applicableWindow of implantation gene expression
    Study

    n: not reported in source

    Comparator
    buserelin 0.6 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (standard) and 2 mg/day (high)As given in this study (human).

    Source sentences

    Summary
    For window of implantation genes, expression patterns were closer to those in the natural cycle following standard- or high-dose ganirelix than after buserelin administration.
    4 context sentences
    Summary · context
    This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles.
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.
    Summary · context
    Gene expression profiles were also studied.
  4. 04HumanNon-randomized trialMechanism

    In oocyte donors, all studied endometrial parameters at HCG +2 were similar with high-dose versus standard-dose ganirelix.

    In plain wordsIn oocyte donors, all studied endometrial parameters at HCG +2 were similar with high-dose versus standard-dose ganirelix.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedEarly luteal endometrial parameters
    Study

    n: not reported in source

    Comparator
    standard-dose ganirelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 mg/dayAs given in this study (human).

    Source sentences

    Summary
    At HCG +2, all the parameters studied were similar in all the groups and comparable to those observed in the natural cycle.
    2 context sentences
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.
  5. 05HumanNon-randomized trialMechanism

    In oocyte donors, all studied endometrial parameters at HCG +2 were similar with standard-dose ganirelix versus buserelin.

    In plain wordsIn oocyte donors, all studied endometrial parameters at HCG +2 were similar with standard-dose ganirelix versus buserelin.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedEarly luteal endometrial parameters
    Study

    n: not reported in source

    Comparator
    buserelin 0.6 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Source sentences

    Summary
    At HCG +2, all the parameters studied were similar in all the groups and comparable to those observed in the natural cycle.
    2 context sentences
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.
  6. 06HumanNon-randomized trialMechanism

    In oocyte donors, all studied endometrial parameters at HCG +2 were similar with high-dose ganirelix versus buserelin.

    In plain wordsIn oocyte donors, all studied endometrial parameters at HCG +2 were similar with high-dose ganirelix versus buserelin.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedEarly luteal endometrial parameters
    Study

    n: not reported in source

    Comparator
    buserelin 0.6 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 mg/dayAs given in this study (human).

    Source sentences

    Summary
    At HCG +2, all the parameters studied were similar in all the groups and comparable to those observed in the natural cycle.
    2 context sentences
    Summary · context
    Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol).
    Summary · context
    Vaginal progesterone (200 mg/day) was administered in the luteal phase.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.